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S_nmary Recently, Ewing's tumours have been shown to carry specific hybrid transcripts resulting from the
fusion of the EWS gene with FLI-1 or ERG genes. Based on the sensitivity and specificity of the detection of
these alterations by the reverse transcriptase-polymerase chain reaction technique, we have developed an
assay to search for small numbers of Ewing cells in various sites from patients with Ewing's tumour. This
method enables the detection of fewer than one tumour cell per million blood mononuclear cells. A total of 28
primary sites and 51 peripheral samples from 36 patients were investigated. Tumour cells could be detected in
4/'18 blood samples, 4/15 bone marrow aspirates and 2/18 peripheral stem cell harvests. EWS/FLI-1 and
EWS/ERG transcripts being observed in eight and two cases respectively. The type of fusion transcript
detected in peripheral site(s) was identical to that observed in the primary site. At diagnosis 5/16 patients
(31%) demonstrated either circulating tumour cells or/and occult bone marrow metastasis. After induction
therapy, tumour cells were detected in 3/21 patients. This highly sensitive method should be a relevant tool to
allow a more accurate clinical assessment of the dissemination of Ewing's tumours.
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Ewing's tumour is the second most frequent primary bone
tumour in children. Despite an incrase in the overall sur-
vival of patients with Ewing's tumour owing to the use of
systemic chemotherapy, the overall long-term survival is still
limited to 50-60% of patients in recent series (Horowitz et
al., 1993). A major prognostic factor is the presence or
absence of disseminated disease. The most frequent metas-
tatic sites are lung, bone and bone marrow, which are
attained through an haematogenous route (Horowitz et al.,
1993). Presently, the detection of metastasis relies on imaging
evaluation of lung and bone and on cytological and his-
tological analysis of bone marrow. However, in the absence
of specific markers for Ewing cells, only an important con-
tamination of bone marrow can be detected suggesting that
the number of patients with metastatic tumours at diagnosis
might be underestimated. Thus, sensitive detection of tumour
cells in peripheral blood or bone marrow may be important
for staging and follow-up.
The recent cloning of the specific chromosome transloca-
tion t(1l;22Xq24;ql2) which characterises Ewing's tumours
has provided a new, promising marker (Aurias et al., 1983;
Turc-Carel et al., 1983; Delattre et al., 1992; Zucman et al.,
1992). Indeed, this chromosome alteration results in a fusion
gene by juxtaposing the EWS gene on chromosome 22 and
the FLI-I gene on chromosome 11 (Delattre et al., 1992). In
a subset of tumours, as a result of a rearrangement between
chromosome 22 and 21, the EWS gene is fused with another
member of the Ets family of transcription factors highly
homologous to FLI-J, the ERG gene (Zucman et al., 1993a;
Sorensen et al., 1994). These fusion genes encode fusion
transcripts which can be detected by the specific amplification
of the junctional region using the reverse transcriptase-
polymerase chain reaction (RT-PCR) technique. Analysis of
large series of small round cell tumours in children has
shown that at least 95% of Ewing tumours are associated
with either an EWS/FLI-I or an EWS/ERG fusion transcript
which, therefore, constitutes a specific marker for this group
of tumours (Delattre et al., 1994; Giovannini et al., 1994).
Tumour-specific gene alterations resulting from
chromosomal translocations are frequent in leukaemias and
lymphomas (Cline, 1994). Their identification, which relies on
highly sensitive PCR-based methods, is now widely used to
detect small numbers of tumour cells in blood, bone marrow
or stem cell harvests from patients.
Solid tumours demonstrating such specific markers are
rarer. However, they constitute a model system for the study
of the metastatic process and for the appreciation of the
clinical applications linked to the use of such highly sensitive
techniques in the detection of malignant cells in solid
tumours.
In this study, we describe a method, based on the nested
PCR amplificiation of the EWS/FLI-I or ERG fusion trans-
cripts, which enables the detection of small numbers of
Ewing cells in biological samples. This technique was applied
to detect the EWS/FLI-I or ERG fusion transcripts from
mononuclear cells isolated from blood, bone marrow and
peripheral stem cell harvests in patients suffering from
Ewing's tumour.
Matedak and mthods
Patients
The study population consisted of 36 patients treated for
Ewing's tumour from 1992 to 1993. Sixteen patients were
analysed at diagnosis, before treatment. Eighteen patients
were studied after induction therapy, at the time of bone
marrow or peripheral stem cell harvests. Two patients were
analysed at the time of relapse; both had lung metastasis.
Finally, three patients could be studied both at diagnosis and
at the time of stem cell harvest.
Samples
Tumour fragments from the primary sites were immediately
frozen in liquid nitrogen. Blood and bone marrow samples
were collected on EDTA and shipped to the laboratory at
room temperature. For each patient, bone marrow aspirates
obtained from six different sites were pooled for analysis. All
samples were received less than 24 h after shipping. At
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receipt, mononuclear cells were immediately isolated by
Ficoll gradient before freezing at -80C.
Isolation ofRNA
Total RNAs were isolated using the RNAzol extraction cit
(Bioprobe systems, France). Sampls were pr d at a site
separate from the ones used for amplification and elect-
rophoresis of PCR products to minunise the potential for
PCR carry-over.
RT-PCR experiments
Primers used in this study are descrbed in Table I. Primary
tumour samples were analysed as previously described
(Delattre et al., 1994). RNA isolated from 1 ml of blood
(1-3pg) or 2jg of RNA isolated from lecapheresis or bone
marrow sampls were reverse transcribed usig 20 ng of
primer 22A and 100 ng ofeither primer 1 lA or ErgA depen-
ding on the type of fusion tanscript in the primary
tumour. Reverse transcriptase reaction was performed in a
20pi volume. As a control, 2 id ofthis reaction was used in a
test ampification of the EWS cDNA usng primers 22.8 and
22.5. EWS/FLI-I tranripts were sought by a nested PCR
amplification procedure. In order to minimise the risk of
sample-to-sample contamination, the two PCR reactions
were performed sequentially in the same tube without open-
ing the tube between the two rounds of amplficaton. In
brief, the first PCR reaction was performed in a volume of
5O 1 con 15MI of the reverse transciptase reaction, 5
pmol of primers 22.8 and Fli. l and 3 units of Taq
polymerase (Perkin Elmer Cetus, Norwalk, CIT, USA). This
mixture was overlaid with 100Id silicon oil (Silicon6l NM1-
350, Promecome), itself overaid with 75pi of a second mix
coning 50 pmol of nested primers 22.3 and Fli.3. This
second mix did not contain the enzyme. After 15 rounds of
PCR amplification, tubes were subjected to a quick cent-
rifugation, which resulted in the mixing of the upper and
lower aqueous phases. A second round of amplification was
then carried out for 35 cycles. For the detection of EWSI
ERG fusion, the same procedure was performed except that
primers Erg.1 I and Erg.3 were used in plac of prmes Fli. I
and Fli.3. All PCR amplification reactions were performed
using the GeneAmp RNA PCR kit (Perkin Elmer Cetus) in
1.5 mm magnesium chloride with the following parameters:
denaturation at 94-C for 30 s, annealing at 68-C for 1 min
and extension at 72-C for 1 min. Amplified products were
analysed on 1.2% TBE agarose gel then blotted by the
Southern procedure and hybridised with primer 22.7.
Resds
Reconstitution experiments
To assess the ability of RT-PCR to detect minimal con-
taminating Ewing's cells in biological samples, variable
amounts of the IARC EW24 cell line, which expresses the
most frequent type 1 EWS/FLI-l transcript (Deattre et al.,
1992), were added to 10 ml aliquots of blood from a healthy
donor. Total RNA was isolated and one-tenth of each sam-
ple.(the amount of RNA equivalent to that contained in 1 ml
of blood) was subjected to reverse transcriptase with pruners
specific for the EWS and the EWS/FLI-I transcipts. Since
the EWS gene is always expressed from the normal allele in
Ewing's tumour, amplification of the EWS transcript with a
single round of 30 cycles of PCR amplification provided a
test amplification. Analysis of EWS/FLI-I transcript was
performed by a nested PCR amplification. In independent
experiments conducted with different healthy donors and
independent dilutions, the EWS/FLI-I fusion transcript was
detected up to the highest dilution studied, which correspond
to two cells per ml of blood (Figure 1). Identical sensitivity
was achieved for the detection of EWS/ERG fusion when the
LARC EW 3 cell line, which expresses an EWS/ERG fusion
transcript, was used for the reconstitution experiments. In
order to obtain an independent measure ofthis sensitivity, we
performed serial dilutions of Ewing's cell RNA with 1 jig of
HeLa cell RNA. In these conditions, 10 pg of Ewing RNA,
the approximate amount of RNA contained in one cel,
promoted amplification of the specific fusion transcript (data
not shown). Taken altogether these experiments demon-
strated that this PCR assay enabled the dection of 1-2 cells
per ml of blood, thus providing a senstivity higher than one
tumour cell per million peripheral blood mononuclear cells.
Analysis ofsamplesfrom patients
This procedure for detection of tumour cells was used to
analyse 51 sampks from 36 patients suffering from Ewing's
tumour. Analysis of the fusion transcript could be performed
a
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F%gw 1 Detetion of the EWS/FL-) fusio transcripts in
reconstitution experiments. RT-PCR was performed on serial
dilution of IARC EW24 Ewing's cells in blood from a healthy
donor. The number of cells in each sample is iated at the top.
C, water control. (a) amplification of the EWS gene expressed by
both tumour and non-tumour cell. (b) amplifiction ofthe EWSI
FL!-1 gene specific for tumour cell.
EWS
Table I Oligonuclootides used for the RT-PCR amplfaon of EWS/FL!-I and
EWS/ERG tanscis
Namw
ofthepimer Gene/exon Sequence
22A EWS/exon 17 5'-GGT AGTCAATGCAGCTCTG-3'
22.8 EWS/exon 7 5'-CCCACTAG1TTACCCACCCCAAA-3'
22.7 EWS/exon 7 5'-AACAGAGCAGCAGC3TACGGGCA-3'
22.5 EWS/exon 12 5'-GGCTITCCTGTTTCCTTGTCC-3'
22.3 EWS/exon 7 5'-TCCTACAGCCAAGCTCCAAGTC-3'
IIA FLI-)/exon 9 5'-AGAAGGGTACiTiGTACATGG-3'
Fli.11 FLI-)/exon 8 5'-AGGGITGGCTAGGCGACTGCT-3'
Fi. 3 FL-I)/exon 8 5'-GTCGGGCCCAGGATCTGATAC-3'
Erg A ERG/exon 9- 5'-TGAGGGGTACTTGTACAGA-3'
Erg 11 ERG/exon 9' 5'-TGTTGGG1TTTGCTCTTCCGCTC-3'
Erg 3 ERG/exon 9 5'-ACTCCCCGlTGGTGCCTlCC-3'
'ThenumberingofERGexonsisindctedassuminganidenfti genomicorganisation
for ERG and FLI-).
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on primary tumours in 28 cases. It revealed 11 type 1, six
type 2, nine other EWS/FLI-I transcripts and two EWS/
ERG transcripts (Zucman et al., 1993a; Delattre et al., 1994).
For the other- eight cases, tumour samples were not available
for the analysis of the primary site. In the absence of any
indication of the type of fusion transcript, blood,
cytopheresis or bone marrow samples from these eight cases
were analysed with both FLI-1- and ERG-specific primers.
RNA isolated from 18 peripheral blood, 15 bone marrow
and 18 peripheral stem cells harvests demonstrated successful
a
amplification of the EWS sequence. A Ewing-specific fusion
transcript could be detected in four blood, four bone marrow
and two peripheral stem cell samples (Table II and Figure 2),
the type of fusion transcript being EWS/FLI-I in eight cases
(type 1, 5; other type, 3) and EWS/ERG in two cases. In all
cases, these transcripts were identical to that detected in the
primary site (Figure 3). This observation suggested that
neither secondary rearrangements nor alternative splicings
had occurred between the primary and peripheral sites.
Among the 32 patients for whom a fusion transcript could be
CTR-
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Fugwe 2 Detection of Ewing's cells in biological samples from
patients. The results of the RT-PCR analysis of the EWS and
EWS/FLI-I genes in 11 blood sampks are shown. The results of
the amplification of the EWS transcript are indicated at the top.
The two bands observed for EWS result from alterative splicing
of exons 8 and 9. CTR+ indicates control amplfication of
reconstitution samples containing 50, 25 and 2 cells. C-, control
without RNA.
Fugwe 3 Comparison of the fusion transcript observed in the
primary site (T) and peripheral sites (B, blood; BM, bone mar-
row). C, control without RNA. The difference in size is linked to
the different procedures used for detection of EWS/FLI-I trans-
crpts. Cases 3 and 6 expressed type I EWS/FLI-I fusion trans-
cript (Delattre et al., 1992), which promoted the amplification of
a 418 bp fragment with primers 11.11 and 22.8 (used for the
analysis of the primary site) and a 209 bp fragment with primer
22.3 and Fli.3 (used as the second set of primers of the nested
PCR reaction for detection of residual cells). Case no. 18 e-
ressed a type 3 transcript (Delattre et al., 1992), which yielded a
670 bp fragment and a 461 bp fragment.
Tale II Results ofthe analysis ofperipheral samples for the presence of Ewing-specific transcripts
No. ofpositive/No. ofsamples studied
No. ofcases No. ofsamples Blood Bone Marrow Stem cell harvests
At Diagnosis
Localised 14 18 4/13 2/5' ND
Metastatic (lung) 2 2 0/ 2 ND ND
After induction therapy 21 28 0/2 1/8 2/18b
At relapse 2 3 0/1 1/2 ND
Total 39c 51 4/18 4/15 2/18
aOn patient waspositiveinboth bloodandbonemarrow.bTriplicateandduplicatesampkscorresponding
to different leucaphereses for onepatient were analysed in one and two casesrespectively. Neither ofthese
samples demonstrated tumour cells. Three patents were analysed both at diagnosis and after induction
therapy.
Table m Characteristics of patients studied at diagnosis
Case no.
2
4
5
8
9
10
11
12
13
16
17
3
6
7
14
15
Localiation
ofthep*iary
Femur
Sacrum
Rib
Metacarpal
Femur
Ulna
Tibia
Humerus
Spine
Rib
Fibula
Rib
Iliac
Rib
Gluteal
Skull
Type offusion
transcrqfl
Other E/F
Other E/F
E/F type 1
E/F type I
E/F type 2
Other E/F
E/F type 2
Other E/F
E/F type I
E/F type 2
Other E/F
E/F type I
E/F type I
Other E/F
E/F type I
E/E
Detection ofoccult tumour cells
Metastasish Blood Bone marroW
Lung
Lung
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
+
'E/F, EWS/FLI; type I or2 isindicated. OtherE/F referstoothertypesofEWS/FLIfusiontranscript(2).
E{E, EWS/ERG. bAs determined by conventional approache; -, absence ofmetastasis. 'Absence (-) or
presence (+) oftumour cls.
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evidenced by the analysis of either or both the primary and
peripheral sites, peripheral tumour cells could be detected in
7/28 patients with the EWS/FLI-I transcript and in 2/4 with
EWS/ERG. This suggests that the propensity of cells to
ciculate or to metastasise in bone marrow is not linked to
the type of fusion transcipt.
A total of 20 samples from 16 patients were studied at
diagnosis (Table ID). The presence of Ewing's cells in blood
and bone marrow could be demonstrated in 4/13 and 2/5
cases respectively (Tables II and Ill). Two patients (cases
nos. 16 and 17) with lung metastasis at diagnosis did not
exhibit crculating Ewing's cells. In two patients (cases nos. 3
and 15), tumour cells could be det in blood but not in
the bone marrow. In these cases, circulating tumour cells
might be unable to metastasise. Altematively, lalised
metastatic sites in bone marrow may have escaped detection.
In one patient (case no. 14) tumour cells were observed both
in blood and in bone marrow. Interestingly, tumour cells
could be detected in blood and/or bone marrow in 5/9
patients with a central pnmary. In contast, no positve
samples were observed in the seven patients with peripheral
tumours (Table 11)1
After iduction therapy, at the time of stem cell harvests
for myelosuppressive therapy, 28 sample from 21 patients
were analysed. None of these patients had evidence of metas-
tasis at this time as detected by conventional techniques.
Tumour cells could be detected in 1/8 bone marrow and in
2/18 stem cells harvests (Table II) but in neither of the two
blood samples anawlysed (Table H). The three positive samples
were colleted from different patients.
Finally, two patents could be studied at mlapse. Both had
lung metastases. Tumour cells were detected in the bone
marrow of one of them.
The existence of a tumour-specific genetic alteration (i.e. the
EWS/FLI-I or ERG fusion transcripts) which can be
specfically detected by PCR makes Ewing's tumour a model
solid tumour for the detection of residual or minimal disease
by RT-PCR. Such tumour-specific gene alterations resulting
from chromosomal translocations are frequent in
haematological malignanci and are widely used as markers
for the detection of minimal disease. In solid tumours, tissue-
specific markers have been used for the detection of tumour
cells. Indeed, in neuroblastoma, tyrosine hydroxylase or
PGP9.5 transcripts have been shown to be possible markers
for the detection of tumour cells in blood or bone marrow
from neuroblastoma patients (Naito et al., 1991; Mattano et
al., 1992; Burchill et al., 1994). In the same way, tyrosinase,
keratn 19 and prostate-specific antigen have been used to
detect tumour cells in patients with melanoma, breast car-
-cinoma and prostate canc respectively (Smith et al., 1991;
Moreno et al., 1992; Datta et al., 1994). Although the sen-
sitivity of these assays is high, their specificity is reduced by
the occurrence of false-positive results, which may be the
result of illegitimate transcription in non-tumour cells.
We have developed a method which enables the detection
of a small number of tumour cells in blood, bone marrow or
peripheral stem cell harvests from patients with Ewing's
tumour. In contrast to the tissue-specific transcripts
previously used in solid tumours, this method relies on the
detection of a specific tumour marker, thus ensuring an
optimised speificity. Its sensitivity, asessed using reconstitu-
tion experiments, is over 1 cell per million mononuckar
blood cells.
Detection of small numbers of cells by RT-PCR in
biological specimens has to overcome two major drawbacks.
The first is linked to the numerous steps naessary to process
the sample from collection to final purification of RNAs. An
error during any of these steps may result in degraded
RNAs, giving rise to false-negative results. This emphasises
the absolute need for an internal control to verify the quality
of the RNA. In this series, this control was provided by
amplification of the EWS transcript. This amplfication was
performed with one-tenth ofthe cDNAs used for detection of
the fusion transcript with a single round of PCR. Only
samples which promoted a strong amplification of EWS in
these conditions were further analysed for tumour cell detec-
tion. The second major drawback is a result of the risk of
cross-contamination linked to the use of PCR amplfication
techniques, espeially when nested PCR strategies are per-
formed. Such contamination may generate false-positive
results. To avoid this problem, precautions included process-
ing samples at different sites for RNA isolation, PCR amp-
lification and electrophoresis of PCR products. Moreover,
this risk was greatly reduced by processing the two rounds of
PCR amplification without opening the tube. Finally, the
observation that the type of fusion transcript is conistnt
between different tumour sites provides a good control for
the specificity of the detection and lowers the risk of
misinterpretation of the results as a result of sample cross-
contamination given that the primary site and the peripheral
site(s) were not presed at the same time.
This method was evaluated on biological samples from
patients. At diagosis, one-third of the patients presented
with involvement of blood, bone marrow or both. None of
these patients had detectable metastases as evaluated by chest
CT scan and cytohistological examination of the bone mar-
row. This demonstrated that regional disease can be accom-
panied by circulating tumour cells or occult bone marrow
metastasis. The impact of these findings on evolution of the
disease will necessitate long-term follow-up of these and
other patients.
As for other solid tumours, myeloablative therapy with
stem cell grafting is now increasingly used for the treatment
of Ewing's tumours, particularly in high-risk groups
(Horowitz et al., 1993). The recent demonstration that, in
neuroblastoma, malignant cells present in the autologous
bone marrow contribute to relapse (Hill et al., 1994) suggests
that an identical phenomenon could occur in Ewing's tumour
and emphasises the need to test stem cell harvests for tumour
cells before grafting. In Ewing's ,Itumour, the method des-
cribed here now enables evaluationWthe prognostic impica-
tions of the psce of tumour cells in stem cell harvests.
It can be anticipated that a potentially important applica-
tion of the method described here will be the regular follow-
up of blood from patients treated for Ewing's tumour. A
progressive increase in the number ofcirculating tumour cells
might be indicative of a relapse. We are currently developing
a competition assay which should enable precise determina-
tion of the number of tumour cells present in the sample.
Finally, the increasing number of tumour-specific genetic
alterations described in solid tumours raises the possibility
that the approach described here for the Ewing's family of
tumours might be applied for other tumours characterised by
specific fusion transcripts (Crozat et al., 1993; Galili et al.,
1993; Rabbits et al., 1993; Zucman et al., 1993b; Clark et al.,
1994; Ladanyi and Gerald 1994).
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